• Tremfya shows long-term efficacy in plaque psoriasis

    2 days ago - By Healio

    Tremfya has shown high rates of long-term skin clearance in patients with moderate to severe plaque psoriasis in a phase 3 extension study, Janssen Pharmaceutical Companies announced in a press release.
    The randomized, double-blind, placebo and active comparator-controlled VOYAGE 1 trial followed patients for nearly 5 years of treatment with Tremfya , a human monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 and inhibits its interaction with the IL-23 receptor.
    Patients were randomly assigned to receive placebo at weeks 0, 4 and 12, followed by a
    Read more ...